GLP-2-TR 20/40mg Description

GLP-2-TR (Tirzepatide) is a synthetic 39-amino-acid peptide engineered as a first-in-class dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Developed by Eli Lilly, it is built on the native human GIP sequence with engineered modifications that confer GLP-1 receptor activity, enzymatic resistance, and an extended duration of action — including an α-aminoisobutyric acid (Aib) substitution at position 2 to block DPP-4 degradation and a C20 fatty diacid chain conjugated at Lys20 via a gamma-glutamic acid linker for albumin binding.

GLP-2-TR works by simultaneously activating two incretin receptors within a single molecule. Through the GLP-1 receptor it enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite via hypothalamic POMC/AgRP modulation. Through the GIP receptor it further augments insulin response and influences adipose-tissue insulin sensitivity and lipid handling. It is characterized in the research literature as an “imbalanced” dual agonist — near-native potency at GIPR with engineered, desensitization-resistant GLP-1R activity — with a circulating half-life of roughly 5 days, supporting once-weekly research dosing.

Tirzepatide is one of the most extensively characterized incretin agonists in modern metabolic research, with a deep clinical trial record spanning glycemic control and body weight, and structural studies defining its dual-receptor mechanism. It is studied here strictly as a research peptide.

Peptide Information

Lyophilized Peptides:

These peptides are freeze-dried, a process that not only extends shelf life but also preserves the purity and integrity of the peptides during storage. We do not use any fillers in this process. GLP-2-TR should be stored refrigerated and protected from light; keep reconstituted solution refrigerated.

Sealed Vial: 20mg of Lyophilized Powder in 3ml Vial

Sealed Vial: 40mg of Lyophilized Powder in 5ml Vial

CAS No.: 2023788-19-2

Other Names: Tirzepatide, LY3298176, GIP/GLP-1 dual agonist (Acetate)

This Product is Not For Human Consumption and is for Laboratory Use Only. Please Read our Terms and Conditions.

Disclaimer: For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.

GLP-2-TR Research

The following sections explore the diverse applications and mechanisms of GLP-2-TR (Tirzepatide) across multiple research domains. As the first-in-class dual incretin receptor agonist, it has a deep and rapidly growing clinical and structural research record in metabolic science.

This overview synthesizes key findings on its dual-receptor mechanism and research applications in glycemic control and body weight.

Dual Incretin Receptor Mechanism

Tirzepatide’s defining feature is unimolecular dual agonism of GIPR and GLP-1R. Structural research using cryo-electron microscopy and molecular dynamics has characterized how its fatty-acid modification and engineered amino-acid sequence determine its dual-receptor binding — notably activating GIPR much like native GIP while engaging GLP-1R in a manner that produces less agonist-induced receptor desensitization than GLP-1 itself¹.

Glycemic Control Research

Among the most cited findings is the SURPASS-2 trial, a large randomized head-to-head study in type 2 diabetes that compared tirzepatide against a selective GLP-1 receptor agonist. It reported that all tirzepatide doses produced significantly greater reductions in HbA1c and body weight than the comparator — establishing dual incretin agonism as a distinct, higher-efficacy approach to glycemic research².

Body Weight Research

The SURMOUNT-1 trial, a 72-week randomized placebo-controlled study in adults with obesity, reported substantial and sustained dose-dependent body-weight reduction with once-weekly tirzepatide — one of the most influential weight-outcome datasets in metabolic research and a key reference for dual-agonist pharmacology³.

Mechanistic Pharmacology Research

Beyond outcome trials, tirzepatide has been extensively studied as a pharmacological tool. Receptor-occupancy and signaling analyses characterize it as an “imbalanced” dual agonist favoring GIPR engagement, a property proposed to contribute to its efficacy profile and tolerability relative to balanced co-agonism — making it a reference compound for multi-receptor agonist research⁴.

Research Considerations

Across the clinical literature, the most commonly reported effects are gastrointestinal (nausea, vomiting, diarrhea, constipation), generally dose-dependent and associated with titration. The research literature emphasizes that the imbalanced GIPR-favoring profile may moderate the GI signal relative to pure GLP-1R agonism, and study designs routinely account for dose escalation and tolerability. These considerations are routinely accounted for within controlled study protocols.

References

1. Sun, B., Willard, F. S., Feng, D., Alsina-Fernandez, J., Chen, Q., Vieth, M., et al. (2022). Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences, 119(13), e2116506119. https://doi.org/10.1073/pnas.2116506119
2. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
3. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
4. Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532. https://doi.org/10.1172/jci.insight.140532